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DOI 10.1016/j.ccr.2012.05.016SUMMARYCancer cells consume large quantities of nutrients and maintain high levels of anabolism. Recent studies
revealed that various oncogenic pathways are involved in modulation of metabolism. Nrf2, a key regulator
for the maintenance of redox homeostasis, has been shown to contribute to malignant phenotypes of
cancers including aggressive proliferation. However, the mechanisms with which Nrf2 accelerates prolifera-
tion are not fully understood. Here, we show that Nrf2 redirects glucose and glutamine into anabolic path-
ways, especially under the sustained activation of PI3K-Akt signaling. The active PI3K-Akt pathway
augments the nuclear accumulation of Nrf2 and enables Nrf2 to promote metabolic activities that support
cell proliferation in addition to enhancing cytoprotection. The functional expansion of Nrf2 reinforces the
metabolic reprogramming triggered by proliferative signals.INTRODUCTION
Metabolic activities in proliferating cells are fundamentally
different from those in quiescent cells (DeBerardinis et al.,
2008). Quiescent cells invest large amounts of energy in the
maintenance of functional and morphological integrity against
extrinsic and intrinsic insults, including oxidative stress. In
contrast, proliferating cells take up abundant nutrients, including
glucose and glutamine, and shunt their metabolites into anabolic
pathways. The signals that promote cell proliferation direct the
reprogramming of metabolic activities, which pushes quiescent
cells into proliferative states. Recent studies have revealed that
oncogenic pathways involving oncogenes and tumor suppressor
genes, such as c-Myc, p53, and PI3K-Akt, directly promote theSignificance
Nrf2 is an inducible transcription activator for cytoprotection f
has been paid to the role of Nrf2 in cancer cells because th
many human cancers that have poor prognoses. Recent stu
carried out by Nrf2 confer growth advantages on cancer cells. In
themetabolic pathways that enhance cell proliferation in the pre
cancer development bymodulating metabolism in addition to e
current knowledge regarding the role of Nrf2 in the malignant
66 Cancer Cell 22, 66–79, July 10, 2012 ª2012 Elsevier Inc.uptake and metabolism of glucose and glutamine, resulting in
metabolic features that are unique to proliferating cells (Kroemer
and Pouyssegur, 2008; Tong et al., 2009; Dang, 2010).
The pentose phosphate pathway (PPP) generates ribose
5-phosphate (R5P), a critical substrate for the nucleotide
synthesis, and NADPH as reducing equivalents. Although the
PPP is a well-established metabolic pathway, a direct regulator
that activates the PPP during metabolic reprogramming has
yet to be identified. One of the p53 targets, TIGAR, inhibits
glycolysis and diverts the carbon flux into the PPP, resulting in
the passive promotion of the PPP activity (Bensaad et al.,
2006). However, because glycolysis is often facilitated in prolifer-
ating cells, alternative mechanisms that actively promote the
PPP are expected to be involved.rom xenobiotic and oxidative stresses. Increasing attention
e constitutive stabilization of NRF2 has been observed in
dies revealed that antioxidant and detoxification activities
this study, we show that Nrf2 directly or indirectly facilitates
sence of active PI3K-Akt signaling. Thus, Nrf2 contributes to
nhancing cellular stress response. This study expands upon
evolution of cancers.
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Nrf2 Function in Metabolic ReprogrammingNrf2 is a master transcriptional activator of cytoprotective
genes. It activates transcription in response to electrophiles
and reactive oxygen species (ROS) (Itoh et al., 1997; Uruno
and Motohashi, 2011). Under normal conditions, Nrf2 is
constantly ubiquitinated by Keap1 and degraded by the protea-
some. Exposure to the stimuli inactivates Keap1 and stabilizes
Nrf2. Nrf2 then translocates into the nucleus, binds to the antiox-
idant response element (ARE) and activates the transcription of
many cytoprotective genes that encode detoxifying enzymes
and antioxidant proteins. The induction of these genes confers
resistance against xenobiotic and oxidative stresses. Recently,
the constitutive stabilization of NRF2 was found in various
human cancers (Singh et al., 2006; Shibata et al., 2008; Wang
et al., 2008; Kim et al., 2010; Solis et al., 2010; Zhang et al.,
2010). Cancers with high NRF2 levels are associated with poor
prognosis (Shibata et al., 2008; Solis et al., 2010) not only
because of the chemo- and radio-resistance but also the aggres-
sive proliferation (Singh et al., 2008; Zhang et al., 2010). The
molecular mechanisms that allow Nrf2 to promote cell prolifera-
tion have not yet been fully elucidated. To clarify how Nrf2
contributes to cell proliferation, we explored Nrf2 target genes
in cancer cells. Hypothesizing that Nrf2 plays distinct roles in
proliferating cells and quiescent cells, we attempted to identify
a signal that modifies the Nrf2 function.
RESULTS
Nrf2 Activates Genes Involved in the PPP, De Novo
Nucleotide Synthesis, and NADPH Production
NRF2 knockdown repressed the proliferation of cancer cell lines
with constitutive NRF2 accumulation (A549, H2126, LK2 and
EBC1 cells) (Figure 1A), suggesting that NRF2 accelerates the
proliferation of these cells. Knockdown efficiency wasmonitored
by the reduced expression of NAD(P)H:quinone oxidoreductase
1 (NQO1), one of the typical target genes of NRF2 (Figure 1B; Fig-
ure S1A available online).
To identify the target genes of NRF2 responsible for cell prolif-
eration, we performed microarray analysis in A549 cells treated
with NRF2 siRNA or control siRNA. A549 is a lung cancer cell
line in which NRF2 is constitutively stabilized due to a somatic
mutation in the KEAP1 gene (Taguchi et al., 2008) and the hyper-
methylation of the KEAP1 promoter (Wang et al., 2008). We used
three independent NRF2 siRNAs and selected genes whose
expression levels were reduced to less than 66.7% of that of
the control sample by all three siRNAs to minimize off-target
effects (Table S1). In addition to the typical target genes of
NRF2 encoding detoxifying enzymes and antioxidant proteins
(cytoprotective genes), genes whose products are involved in
the PPP (glucose-6-phosphate dehydrogenase [G6PD], phos-
phogluconate dehydrogenase [PGD], transketolase [TKT], and
transaldolase 1 [TALDO1]) and de novo nucleotide synthesis
(phosphoribosyl pyrophosphate amidotransferase [PPAT] and
methylenetetrahydrofolate dehydrogenase 2 [MTHFD2]) were
decreased by the NRF2 knockdown (Figure 1B). Genes encod-
ing enzymes for NADPH synthesis (malic enzyme 1 [ME1] and
isocitrate dehydrogenase 1 [IDH1]) were also decreased (Fig-
ure 1B). The NRF2 knockdown did not affect the expression
levels of four unrelated genes (MDM2, CREBBP, EGFR, and
ERBB2) or the abundance of the ribosomal RNA primary tran-script (pre-rRNA) (Figure 1B). These results indicate that the
genes involved in themetabolism (metabolic genes) were specif-
ically repressed by the NRF2 knockdown and exclude the possi-
bility that cell activities were generally impaired in NRF2-knock-
down cells. We also confirmed the reduction of the enzyme
proteins encoded by these genes in the NRF2-knockdown cells
(Figure 1C). A time-course of the gene expression was consis-
tent with the blunted increase in cell number (Figure S1B and
Figure 1A).
We then performed global mapping of NRF2 binding sites in
A549 cells using ChIP-seq analysis (to be published elsewhere).
By integrating the results of the ChIP-seq and microarray anal-
yses, we found that NRF2 directly activates G6PD, PGD, TKT,
TALDO1,ME1, and IDH1 through well-conserved AREs (Figures
1D and S1C). The ChIP-seq results were validated for each locus
using quantitative polymerase chain reaction (PCR) (Figure 1E).
The expression of these genes depended on NRF2 in three other
cell lines with constitutively stabilized NRF2 (Figure S1A).
Although the peaks in the PPAT and MTHFD2 loci from the
ChIP-seq analysis were not validated by quantitative PCR
(data not shown), the abundance of PPAT andMTHFD2mRNAs
was similarly decreased by NRF2 knockdown in these cell lines
(Figure S1A).
Nrf2 Promotes Purine Nucleotide Synthesis and
Glutamine Metabolism
To elucidate the contribution of NRF2 to cellular metabolic activ-
ities, we performed metabolomic profiling using capillary elec-
trophoresis mass spectrometry (CE-MS) in A549 cells treated
with NRF2 siRNA or control siRNA (Figure 2). Consistent with
our finding that NRF2 activates the expression of enzymes for
PPP and nucleotide synthesis (Figure 2A), NRF2 knockdown
significantly increased the levels of glycolytic intermediates,
such as G6P, F6P, DHAP, pyruvate, and lactate (Figure 2B).
The effect was more obvious at 48 hr after siRNA introduction
than at 24 hr (Figure 2B; Tables S2 and S3). PRPP and IMP,
the first product of the purine nucleotide synthesis, were
decreased whereas the PPP intermediates (i.e., 6-PG, Ru5P,
R5P and S7P) were increased (Figure 2C). These results were
validated by a tracer study using [U-13C6] glucose (Figure 2D;
Table S4). Importantly, 100% of IMP detected in the tracer study
was [13C5] IMP, suggesting that the ribose ring (C5) of IMP is all
derived from glucose in A549 cells (Table S4). Thus, the
decrease in IMP in the NRF2-knockdown cells indicates that
NRF2 is required for the efficient purine nucleotide synthesis
from glucose. We did not detect a significant contribution of
NRF2 to the pyrimidine nucleotide synthesis.
To exclude the effect of the salvage pathway of the nucleotide
synthesis, we performed a tracer study with [U-13C6] glucose
using dialyzed fetal bovine serum (FBS) to remove purine bases
from the medium (Figure S2; Table S5). In the NRF2-knockdown
cells, [13C5] IMP and [
13C5] ADP significantly decreased while
metabolites in the PPP, glycolysis, TCA cycle, and serine
synthesis pathway tended to increase, suggesting that the over-
all distribution of the glucose-derived 13C was shifted away from
the purine nucleotide synthesis. These results demonstrated that
the steps from R5P to IMP via PRPP (the post-R5P steps) were
delayed and that the PPP intermediates stagnated in the
NRF2-knockdown cells.Cancer Cell 22, 66–79, July 10, 2012 ª2012 Elsevier Inc. 67
Figure 1. NRF2 Activates Genes Involved in the PPP, Nucleotide Synthesis, and NADPH Production
(A) Effects of NRF2 knockdown on cell proliferation in cancer cell lines with the constitutive stabilization of NRF2. Cells were transfected with siRNA targeting
NRF2 (NRF2 siRNA) or scrambled control siRNA (control siRNA). Initial cell numbers were set to 1.
(B) Effects of NRF2 knockdown on gene expression in A549 cells. The mRNA expression was analyzed at 24 hr after the siRNA transfection. Each panel shows
one representative result from three independent experiments. Average values and SDs were calculated from triplicate samples. Average values for cells treated
with the control siRNA were set to 100. See also Table S1, Figures S1A and S1B.
(C) Immunoblot detection of the PPP enzymes and other metabolic enzymes in A549 cells. Cells were analyzed at 48 hr after the siRNA transfection. aTubulin was
detected as a loading control.
(D) Position and sequence of AREs within each target locus. TSS, transcription start site. Scale bars indicate 1 kbp (1K) or 10 kbp (10K). See also Figure S1C.
(E) Relative enrichment against the input of each locus. The second exon of the NQO1 gene (NQO1 Ex2) was used as a negative control locus, whose
enrichment was set to 1. One representative result from three independent experiments is shown. Average values and SDs were calculated from triplicate
samples.
*p < 0.05; **p < 0.01; ***p < 0.001 (A, B, and E).
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Nrf2 Function in Metabolic ReprogrammingOne unexpected finding was a marked increase in glutamine
and glutamate in the NRF2-knockdown cells (Figure 2F), which
was suggestive of the critical contribution of Nrf2 to glutamine
metabolism. The tracer study using [U-13C5] glutamine demon-
strated the primary distribution of carbons derived from gluta-
mine (Table S6). The two major directions of the metabolite flux
were toward the glutathione synthesis and TCA cycle (Figure 2E).
Remarkably, NRF2 knockdown affected glutathione synthesis,
decreasing the levels of 13C-labeled GSH andGSSG (Figure 2G).
This result is consistent with previous reports demonstrating that68 Cancer Cell 22, 66–79, July 10, 2012 ª2012 Elsevier Inc.Nrf2 activates both genes encoding the catalytic and regulatory
subunits of gamma-glutamyl-cysteinyl-ligase (GCL), a rate-
limiting enzyme of glutathione synthesis (Lu, 2009). Indeed, the
knockdown of KEAP1 and NRF2 in HaCaT cells increased and
decreased glutathione, respectively (MacLeod et al., 2009), indi-
cating that Nrf2 plays an important role in glutathione synthesis.
Another notable result of NRF2 knockdown was an increase in
[U-13C4] malate and a decrease in [U-
13C3] lactate (Figure 2G),
suggesting that lactate production from glutamine is inhibited.
This result likely reflects the reduced activity of ME1 (Figures
Figure 2. NRF2 Knockdown Alters Glucose and Glutamine Metabolism in A549 Cells
(A) Metabolic enzymes regulated by NRF2 in glucose metabolism.
(B andC) Quantification ofmetabolic intermediates in glycolysis (B) and the PPP and purine nucleotide synthesis (C). Metabolite concentrations were quantified at
24 and 48 hr after the transfection of siRNAs. See also Tables S2 and S3.
(D) Tracer study using [U-13C6] glucose. A549 cells transfected with control siRNA or NRF2 siRNA were incubated with [U-
13C6] glucose for 1 hr and analyzed.
Ratios of isotopomer concentrations in NRF2-knockdown (KD) samples versus control samples are shown. See also Tables S4 and S5 and Figure S2.
(E) Metabolic enzymes regulated by NRF2 in glutamine metabolism.
(F) Quantification of metabolic intermediates in glutathione synthesis and glutaminolysis. Metabolite concentrations were quantified at 24 and 48 hr after the
transfection of siRNAs. See also Tables S2 and S3.
(G) Tracer study using [U-13C5] glutamine. A549 cells transfected with control siRNA orNRF2 siRNAwere incubated with [U-
13C5] glutamine for 6 hr and analyzed.
Ratios of isotopomer concentrations in NRF2 KD samples versus control samples are shown. See also Table S6.
All samples were analyzed in triplicate. Error bars indicate SDs. *p < 0.05; **p < 0.01; ***p < 0.001 (B, C and F).
1,3-BPG, 1,3-bisphosphoglycerate; 2-OG, 2-oxoglutarate; 2-PG, 2-phosphoglycerate; 3-PG, 3-phosphoglycerate; 6-PG, 6-phosphogluconate; 6-PG1,5L,
6-phosphoglucono-1,5-lactone; 5-PRA, b-5-phosphorybosylamine; DHAP, dihydroxyacetone phosphate; F1,6P, fructose 1,6-bis-phosphate; F6P, fructose
6-phosphate; G6P, glucose 6-phosphate; GSSG, glutathione (oxidized); GSH, glutathione (reduced); GAP, glyceraldehyde 3-phosphate; IMP, inosine
50-monophosphate; PEP, phosphoenolpyruvate; PRPP, phosphoribosyl pyrophosphate; R5P, ribose 5-phosphate; Ru5P, ribulose 5-phosphate; S7P, sedo-
heptulose 7-phosphate.
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Figure 3. Functional Contribution of the PPP
Enzymes to Cell Proliferation In Vitro and In Vivo
(A) Knockdown efficiencies ofG6PD and TKT in A549 cells
were examined by quantitative RT-PCR. Average values
for cells treated with the control siRNA were set to 100.
(B) Effect of simultaneous knockdown of G6PD and TKT
on cell proliferation. Relative cell numbers are shown.
Cells were counted at 72 hr after transfection.
(C) Effect of simultaneous knockdown of G6PD and TKT
on tumor growth in vivo. Mice transplanted with A549 cells
were treated with control siRNA (n = 6), NRF2 siRNA
(n = 5), or G6PD+TKT siRNA (n = 6).
(D) Tumor weight on day 28 after the first siRNA treatment.
(E) mRNA expression of siRNA targets (NRF2, G6PD, and
TKT) in tumors. The tumors were injected with control
siRNA (n = 6 for day 5; n = 3 for day 21), NRF2 siRNA (n = 6
for day 5; n = 3 for day 21), or G6PD+TKT siRNA (n = 5 for
day 5; n = 3 for day 21) and processed for RNA purification
at 5 or 21 days after the initial injection.
Average values and SDs were calculated from triplicate
samples.Averagevalues for cells treatedwithcontrol siRNA
were set to 100. *p < 0.05; **p < 0.01; ***p < 0.001 (A-E).
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Nrf2 Function in Metabolic Reprogramming1B and 1C), which catalyzes the oxidative decarboxylation of
malate and the production of NADPH. Indeed, the enzymatic
activity of ME1 has been suggested to be responsible for gluta-
minolysis (DeBerardinis et al., 2007). Nrf2 thus facilitates gluta-
minolysis by activating ME1.
Nrf2 Requires the PPP Enzymes to Accelerate Tumor
Growth
Since the inhibitory effect of the NRF2 knockdown on the post-
R5P steps seemed to dominate over that on the PPP in the70 Cancer Cell 22, 66–79, July 10, 2012 ª2012 Elsevier Inc.metabolite analysis, we separately evaluated
the significance of the PPP for Nrf2-dependent
proliferation. We examined the necessity of the
PPP activity in NRF2-overexpressing cells by
knocking down G6PD and TKT, which are
involved in the oxidative and non-oxidative
arms of the PPP, respectively (Figure 3). We
used A549 cells in which NRF2 is abundantly
expressed. The simultaneous knockdown of
G6PD and TKT significantly repressed cell
number increase after 72 hr of transfection
(Figures 3A and 3B). The knockdown effect on
tumor growth in vivo was examined in a xeno-
graft experiment. Four weeks after A549 cells
were transplanted into nude mice, the siRNA
was injected into the tumor. Tumor growth
was dramatically repressed by the injection of
NRF2 siRNA (Figure 3C). A previous study re-
ported the therapeutic efficacy of the local injec-
tion of NRF2 siRNA in a xenograft experiment
(Singh et al., 2008), which was reproducible in
our system. We further examined the efficacy
of the double knockdown of G6PD and TKT.
The simultaneous injection of siRNAs against
G6PD and TKT was also effective for the inhibi-
tion of tumor growth (Figure 3C). The average
tumor weight was significantly reduced by thedouble knockdown compared with the control samples (Fig-
ure 3D). Thus, the highly expressed NRF2 in A549 cells was
insufficient to overcome the inhibitory effect on cell proliferation
resulting from the G6PD and TKT knockdown. These data are
consistent with a model in which G6PD and TKT are requisite
downstream targets for NRF2 to support A549 cell proliferation.
The siRNA treatment of the tumor reduced the expression of
the respective gene by approximately 40%–50% on day 5 (Fig-
ure 3E, upper panels), whereas no difference was detected on
day 21 (Figure 3E, lower panels). These results suggest that
Figure 4. Effects of Nrf2 Overexpression
in Cultured Cells
(A) Gene expression in 293/CAT and 293/FLAG-
Nrf2 cells. Cells were treated with or without 1 mg/
ml tetracycline for 24 hr. Average values for each
cell without tetracycline were set to 1.
(B) Immunoblot analysis of Nrf2 in nuclear
fractions of 293/CAT and 293/FLAG-Nrf2 cells.
LaminB was detected as a loading control. Cells
were treated with or without 1 mg/ml tetracycline
for 24 hr.
(C) Gene expression in Jurkat cells transfected
with pmaxGFP, pcDNA3-mNrf2 and p3xFLAG-
Nrf2. Cells were harvested at 24 hr after the
transfection. Average values for cells transfected
with pmaxGFP were set to 1.
(D) Gene expression in WT and Keap1/ MEFs.
Average values for the WT MEFs were set to 1.
(E) Immunoblot analysis of Nrf2 in WT and
Keap1/ MEFs. LaminB was detected as a
loading control.
(F) Tracer study using [U-13C6] glucose. WT and
Keap1/ MEFs were cultured with dialyzed FBS
and incubated with [U-13C6] glucose for 1 hr.
Ratios of isotopomer concentrations in Keap1/
MEFs versus WT MEFs are shown. All samples
were analyzed in triplicate. See also Table S7 and
Figure S3.
(G) Cell proliferation of WT and Keap1/ MEFs.
Initial cell numbers were set to 1.
Average values and SDs were calculated from
triplicate samples. *p < 0.01; **p < 0.001 (A, C, D
and G).
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Nrf2 Function in Metabolic Reprogrammingthe suppression of NRF2 activity or the PPP activity for a limited
period sufficiently delayed tumor outgrowth and had a prolonged
effect on tumor size.
Increased Expression of Nrf2 Alters Metabolic Activities
and Enhances Proliferation in Cultured Cells
We next examined the effect of the increased Nrf2 on gene
expression. 293/FLAG-Nrf2 and 293/CAT are stable cell lines
that inducibly express FLAG-tagged Nrf2 and chloramphenicol
acetyltransferase (CAT), respectively. After the induction with
tetracycline, NQO1, one of the cytoprotective genes, and the
metabolic genes were elevated in 293/FLAG-Nrf2 cells but not
in 293/CAT cells (Figure 4A). The nuclear accumulation of Nrf2
was confirmed in 293/FLAG-Nrf2 cells treated with tetracycline
(Figure 4B). When Nrf2 was overexpressed in Jurkat cells, in
which Nrf2-mediated antioxidant response was augmented
due to a frame-shift mutation in the PTEN gene (Sakamoto
et al., 2009), NQO1 and the metabolic genes were upregulated
with the exception of ME1, whose expression was not detected
in Jurkat cells (Figure 4C). We then examined the effect of the
forced stabilization of endogenous Nrf2 by adopting Keap1/
mouse embryonic fibroblasts (MEFs). Keap1/MEFs displayed
abundant nuclear accumulation of Nrf2 and higher expression of
the metabolic genes than wild-type (WT) MEFs (Figures 4D and
4E). Thus, Nrf2 activates the metabolic genes when it is highly
expressed in cultured cells.
To examine the effect of Nrf2 increase on the nucleotide
synthesis, Keap1/ and WT MEFs were subjected to the tracerstudy using [U-13C6] glucose and dialyzed FBS. In Keap1
/
MEFs, [13C5] IMP, [
13C5] AMP, and [
13C5] ATP significantly
increased while metabolites in the PPP, glycolysis, TCA cycle
and serine synthesis pathway tended to decrease, suggesting
that the overall distribution of the glucose-derived 13Cwas shifted
toward the purine nucleotide synthesis (Figures 4F and S3; Table
S7). Thepost-R5Pstepswere facilitated inKeap1/MEFs,which
was just opposite to the effect ofNRF2-knockdown in A549 cells.
We then examined the effect of Nrf2 accumulation on cell
proliferation. The cell number increase was much faster in
Keap1/ MEFs than in WT MEFs (Figure 4G). When the exoge-
nous Nrf2 was transiently expressed in 293T cells, in which the
basal Nrf2 protein is hardly detected (Figure 5A, left panel), the
cell number increase was significantly accelerated (Figure 5B),
and the Nrf2 target genes were activated (Figure 5C). These
effectswere not observedwhen themutant Nrf2 (Nrf2CT) lacking
the activation domain was expressed (Figures 5A, right panel, 5B
and 5C). Thus, Nrf2 enhanced the proliferation of 293T cells,
which depended on its transcriptional activation ability.
Since 293T cells turned out to display Nrf2-dependency in cell
proliferation, we used 293T cells for analyzing the contribution of
the PPP to proliferation as a downstream pathway of Nrf2. The
cell number increase was significantly accelerated upon the
expression of the exogenous G6PD or TKT (Figures 5D and
5E), indicating that selective increase of G6PD or TKT acceler-
ated proliferation without activating the other Nrf2 target genes.
Thus, the enhancement of the PPP activity accounts for the Nrf2-
dependent cell proliferation at least in part.Cancer Cell 22, 66–79, July 10, 2012 ª2012 Elsevier Inc. 71
Figure 5. Increased Expression of Nrf2 or the PPP Enzymes Acceler-
ates Cell Proliferation
(A) Immunoblot analysis of 293T cells expressing FLAG-Nrf2 and FLAG-Nrf2
CT. FLAG-Nrf2 was detected with anti-Nrf2 (left panel) and anti-FLAG (right
panel) antibodies. LaminB was detected as a loading control.
(B) Effect of increased expression of Nrf2 on cell proliferation. FLAG-Nrf2 or
FLAG-Nrf2 CT was expressed in 293T cells. Relative cell numbers are shown.
The number of cells expressing LacZ was set to 1. Cells were counted at 96 hr
after transfection.
(C) Gene expression in 293T cells transfected with an expression vector
encoding LacZ, FLAG-Nrf2 or FLAG-Nrf2 CT. Cells were harvested at 48 hr
after the transfection. Average values for cells expressing LacZ were set to 1.
(D) Immunoblot analysis of 293T cells expressing exogenous G6PD (left) and
TKT (right). Arrowheads and arrows indicate endogenous and exogenous
enzymes, respectively.
(E) Effect of increased expression of G6PD or TKT on cell proliferation. Relative
cell numbers are shown. The number of cells expressing LacZ was set to 1.
Cells were counted at 96 hr after transfection.
Average values and SDs were calculated from triplicate samples. *p < 0.01
(B, C and E).
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Nrf2 Function in Metabolic ReprogrammingNrf2 Accumulation Promotes Cell Proliferation
in the Forestomach Epithelium
Our next question was how Nrf2 contributes to the cell prolifera-
tion in normal cells in vivo. We utilizedKeap1F/mice as a source72 Cancer Cell 22, 66–79, July 10, 2012 ª2012 Elsevier Inc.of non-cancer cells with abundant Nrf2 protein (Taguchi et al.,
2010). While the expression of Nqo1 was clearly higher in
Keap1F/ mice in all the tissues examined, the metabolic genes
were significantly activated in the forestomach and intestine but
not in the liver (Figure 6A). These results suggest that Nrf2
induces the metabolic genes in the forestomach and intestine
but does not do so efficiently in the liver. Comparison of Nrf2/
and WT livers suggested that Nrf2 contributes to the basal
expression rather than the inducible expression of the metabolic
genes in the liver (Figure S4).
Because of the most marked induction of the metabolic genes
by Keap1 reduction, we focused on the forestomach. Corre-
sponding to the elevated gene expression, the enzyme protein
levels were dramatically higher in the Keap1F/ forestomachs
than the control samples (Figure 6B). The metabolic intermedi-
ates of glycolysis and the PPP were all decreased in the
Keap1F/ forestomachs (Figure 6C). Hypoxanthine, xanthine
and uric acid were all robustly increased in place of IMP
(Figure 6C), implying that the excessive IMP may have been
converted to uric acid (Figure 2A). These results were almost
consistent with the metabolite pattern in Keap1/ MEFs.
We then histologically examined the cell proliferation in the for-
estomach epithelia. In the Keap1F/ forestomach, the epithelial
layer was hypertrophic, and abundant Nrf2 accumulation was
clearly observed (Figure 6D). These results are consistent with
those of our previous reports (Wakabayashi et al., 2003; Taguchi
et al., 2010). The incorporation of BrdU was enhanced in the
Keap1F/ forestomach (Figure 6D), suggesting that the accumu-
lated Nrf2 provokes cell proliferation leading to the epithelial
hypertrophy.
To validate the Nrf2-dependency of the phenotypes caused by
the Keap1 reduction, we examined the forestomach epithelia in
Keap1/::Nrf2/ mice. The expression of the metabolic genes
in the forestomach wasmostly comparable betweenNrf2/ and
Keap1/::Nrf2/ mice (Figure 6E) and between WT and
Nrf2/ mice (Figure S4), indicating that Keap1/::Nrf2/
mice showed no or only marginal increase of the metabolic
genes compared with WT mice. Neither epithelial hypertrophy
nor enhanced incorporation of BrdU was seen in the
Keap1/::Nrf2/ mice (Figure 6D). These results indicate that
the accumulated Nrf2 is responsible for the phenotypes
observed in Keap1F/ mice. Thus, Nrf2 activates metabolic
genes, modulates the metabolite pattern and provokes cell
proliferation when it accumulates in forestomach epithelial cells.
Nrf2 Enhances Metabolic Gene Expression
in the Presence of Active PI3K-Akt Signaling
We were curious why Nrf2 accumulation had different effects on
different tissues in terms of the metabolic gene activation (Fig-
ure 6A). Considering that epithelial tissues of the forestomach
and intestine are composed of proliferating cells and that
approximately 80% of the liver is composed of normally quies-
cent hepatocytes (Taub, 2004), we assumed that Nrf2 could
effectively activate metabolic genes in the presence of prolifera-
tive signals.
The PI3K-Akt signaling pathway is one of the major contribu-
tors to cancer development because it promotes cancer cell
growth, survival, and metabolism (Elstrom et al., 2004; Engel-
man, 2009). We compared the activities of the PI3K-Akt pathway
Figure 6. Effects of Nrf2 Accumulation in Forestomach Epithelia
(A) Gene expression in the forestomach, intestine and liver of WT (n = 6) and Keap1F/ (n = 4) mice. See also Figure S4.
(B) Immunoblot detection of the PPP and NADPH production enzymes in the forestomach epithelia of Keap1F/+ and Keap1F/ mice. aTubulin was detected as a
loading control.
(C) Quantification of metabolic intermediates of glycolysis and the PPP. IMP and its derivatives were alsomeasured. Forestomach epithelia ofKeap1F/+ (n = 3) and
Keap1F/ (n = 3) mice were analyzed.
(D) Histological analysis of the forestomach of Keap1F/+ (n = 4), Keap1F/ (n = 4) and Keap1/::Nrf2/ (n = 3) mice. BrdU and Nrf2 were detected with specific
antibodies (middle and right columns, respectively). Hematoxylin and eosin (HE) staining is shown in the left column. Representative micrographs are shown.
A scale bar corresponds to 50 mm.
(E) Gene expression in the forestomach of Nrf2/ (n = 3) and Keap1/::Nrf2/ (n = 3) mice.
(F) Phosphorylation of Akt in the forestomach, intestine, and liver of Keap1F/– mice. An arrow indicates the phosphorylated Akt at T308.
(G) Immunoblot analysis of Nrf2 in the forestomach, intestine and liver of WT and Keap1F/ mice. An arrow indicates Nrf2. LaminB was detected as a
loading control.
Average values are shown, and error bars indicate SDs (A, C, and E). Average values for WT (A), Keap1F/+ (C) or Nrf2/ (E) were set to 1. *p < 0.05; **p < 0.01;
***p < 0.001 compared with WT (A), Keap1F/+ (C) or Nrf2/ (E).
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tion of Akt (Figure 6F). While the phosphorylation at S473
showed individual variability, the levels of T308 phosphorylation
were markedly different among tissues; they were the highest in
the forestomach, intermediate in the intestine, and almost unde-
tectable in the liver. The phosphorylation at T308 is essential for
the activation of Akt because T308 is positioned at the activationloop of the kinase (Casamayor et al., 1999). The Akt in the forest-
omach was likely to possess the highest activity. The cultured
cells, including A549, 293, Jurkat, and MEFs, where Nrf2 acti-
vates the PPP, also showed the high levels of Akt phosphoryla-
tion at both sites (Figures 7A–7C and 7E). When the PI3K-Akt
signaling was turned off by serum starvation, the highly ex-
pressed metabolic genes in Keap1/ MEFs were decreasedCancer Cell 22, 66–79, July 10, 2012 ª2012 Elsevier Inc. 73
Figure 7. Nrf2 Enhances Metabolic Gene
Expression in the Presence of Active PI3K-
Akt Signaling in Cultured Cells
(A–C) Phosphorylation of Akt in cytoplasmic frac-
tions of A549 cells (A), 293/CAT and 293/FLAG-
Nrf2 cells (B), and Jurkat cells (C). Cells were
treated with 5 mMWortmannin (A–C) or LY294002
(20 mM for A and 50 mM for B and C) for 48 hr (A)
and 3 hr (B and C).
(D) Gene expression in WT and Keap1/ MEFs.
Cells were cultured in the presence or absence of
serum for 48 hr. Average values for the WT MEFs
with serum were set to 1.
(E) Immunoblot analysis of Nrf2 and phosphory-
lated Akt in WT and Keap1/ MEFs. Cells were
cultured in the presence or absence of the serum
for 48 hr. LaminB and total Akt were detected as
loading controls.
(F) Cell number increase of WT and Keap1/
MEFs cultured in the presence or absence of
serum. The time was measured from the start of
serum starvation. Initial cell numbers were set to 1.
(G) Susceptibility to CDNB treatment in WT and
Keap1/ MEFs under normal condition or serum
starvation.
Average values and SDs were calculated from trip-
licate samples. *p < 0.05; **p < 0.001 (D, F and G).
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that Nrf2 requires cooperation from active PI3K-Akt signaling to
fully activate the metabolic genes.
It should be noted that both Keap1/ and WT MEFs ceased
proliferation under serum starvation, indicating that Nrf2
promotes cell proliferation only in the presence of proliferative
signals (Figure 7F). In contrast, Keap1/MEFs were more resis-
tant to the toxicity of 1-chloro-2,4-dinitrobenzene (CDNB) than
WT MEFs with or without serum (Figure 7G), indicating that
Nrf2 enhances cytoprotection irrespective of the activity of prolif-
erative signals. These results implicate the functional expansion
of Nrf2 in the presence of active PI3K-Akt signaling.
Forced Activation of PI3K Allows Nrf2 to Activate
Metabolic Genes
To test this hypothesis, we activated the PI3K-Akt signaling
pathway by deleting Pten in the liver and examined the gene
expression (Figure 8A, left four bars). The livers of mice with
four different genotypes were compared; PtenF/F (Control),
PtenF/F::Alb-Cre (P-Alb), Keap1F/F::Alb-Cre (K-Alb) and PtenF/F::
Keap1F/F::Alb-Cre (P/K-Alb). Because the P/K-Alb mice were
lethal at approximately 3 weeks after birth due to unknown
reasons, all the mice were examined on day 15 (P15). The
K-Alb liver showed a modest increase in the metabolic gene
expression but a robust increase in Nqo1, which is consistent74 Cancer Cell 22, 66–79, July 10, 2012 ª2012 Elsevier Inc.with the results observed in the Keap1F/
liver (Figure 6A). While the P-Alb liver
showed only a slight increase in the
expression of the genes examined, the
P/K-Alb liver showed a marked increase
in metabolic gene expression, even
for Mthfd2, which was not elevated inKeap1F/ tissues (Figure 6A). A comparison of P-Alb and P/K-
Alb showed that theKeap1 deletion robustly increased themeta-
bolic gene expression in addition toNqo1 in the absence of Pten,
suggesting that the Pten deletion potentiates Nrf2 function and
augments the induction of the ARE-driven genes by Nrf2.
To verify the contribution of Nrf2 to the expression of themeta-
bolic genes, we examined the livers of mice in theNrf2 null back-
ground; PtenF/F::Nrf2/ (Nrf2-KO), PtenF/F::Alb-Cre::Nrf2/
(P-Alb/N), PtenF/F::Keap1F/F::Alb-Cre::Nrf2/ (P/K-Alb/N), and
PtenF/F::Keap1F/F::Alb-Cre::Nrf2+/ (P/K-Alb/N-h) (Figure 8A,
right four bars). The gene expression in the P/K-Alb/N liver was
much lower than that in the P/K-Alb liver and as low as that in
the P-Alb liver, indicating that Nrf2 is essential for the marked
elevation of the gene expression in the P/K-Alb liver. The expres-
sion levels ofMe1 and Nqo1 of the P/K-Alb/N-h liver were inter-
mediate between the P/K-Alb and P/K-Alb/N livers. The expres-
sion of the rest of the genes in theP/K-Alb/N-h liver was as low as
that observed in the P/K-Alb/N liver. These results indicate that
the transcriptional activation of the metabolic genes requires
higher Nrf2 activity than the cytoprotective genes.
We further examined the effect of active PI3K-Akt signaling on
the Nrf2 function to modulate the metabolic activity in the liver.
The metabolic intermediates were measured in the livers of
Control, P-Alb, K-Alb, P/K-Alb and P/K-Alb/N mice using CE-
MS (Figure 8B). The abundance of PPP intermediates, IMP and
Figure 8. Forced Activation of PI3K-Akt Signaling in the Liver Enhances Nrf2 Activity
(A) Gene expression in the liver of Control (n = 3), P-Alb (n = 4), K-Alb (n = 4), P/K-Alb (n = 3), Nrf2-KO (n = 6), P-Alb/N (n = 5), P/K-Alb/N (n = 4), and P/K-Alb/N-h
(n = 4) mice.
(B) Quantification of the intermediates of the PPP and glutamine metabolism and IMP in the liver of Control (n = 3), P-Alb (n = 3), K-Alb (n = 3), P/K-Alb (n = 3), and
P/K-Alb/N (n = 3) mice.
(C) Immunoblot detection of Nrf2, Pten, Keap1, and phosphorylated Akt in the liver of Control, P-Alb, K-Alb, P/K-Alb and P/K-Alb/N mice at P15. LaminB
and aTubulin were detected as loading controls.
(D) mRNA expression of Nrf2, Pten, and Keap1 in the liver of Control (n = 3), P-Alb (n = 4), K-Alb (n = 4), P/K-Alb (n = 3), and P/K-Alb/N (n = 4) mice.
(E) Immunoblot detection of Pten and phosphorylated Akt in the livers of Control and P-Alb mice at 10 weeks. aTubulin was detected as a loading control.
Average values are shown, and error bars indicate SDs. Average values for Control samples were set to 1 (A, B, and D). *p < 0.05; **p < 0.01; ***p < 0.001
(compared with Control in panel D).
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suggesting that simple Nrf2 accumulation does not alter the
metabolite pattern. Importantly, the PPP intermediates were
significantly lower in P/K-Alb liver than in P-Alb liver, and the
decrease was restored in P/K-Alb/N liver. IMP tended to be
higher in P/K-Alb than P-Alb, and the increase was not observed
in P/K-Alb/N. Similarly, GSH was significantly higher in P/K-Alb
than P-Alb, and the increase was canceled in P/K-Alb/N. These
results implied that Nrf2 accumulation affects the metabolite
pattern in the presence of active PI3K-Akt pathway.
Forced Activation of PI3K Enhances the Nuclear
Availability of Nrf2
To elucidate the underlying mechanisms of the functional poten-
tiation of Nrf2, we examined the protein abundance of Nrf2 inliver nuclear extracts (Figure 8C). Whereas K-Alb liver showed
slight increases in Nrf2 compared with the Control and P-Alb
livers, nuclear extracts from the P/K-Alb liver contained dramat-
ically increased Nrf2. We also found that Nrf2 mRNA was more
abundant in the P/K-Alb liver compared with the rest of the
mice, suggesting the increased production of Nrf2 in the P/K-
Alb liver (Figure 8D). Thus, the quantitative increase in nuclear
Nrf2 is regarded to be the primary cause of the elevated expres-
sion of Nrf2 target genes in the P/K-Albmice. Importantly, Keap1
protein was barely detectable in either theK-Alb orP/K-Alb livers
(Figure 8C), which indicates that the enhanced nuclear accumu-
lation of Nrf2 is independent of Keap1 deficiency but dependent
on the disruption of the Pten gene. Consistently, the Nrf2 protein
wasmore abundant in the tissues and cells with higher activity of
PI3K-Akt signaling; the forestomach and intestine accumulatesCancer Cell 22, 66–79, July 10, 2012 ª2012 Elsevier Inc. 75
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Nrf2 Function in Metabolic Reprogrammingmore Nrf2 than the liver in Keap1F/– mice (Figure 6G), and
Keap1/ MEFs with serum accumulates more Nrf2 than those
without serum (Figure 7E).
We then examined the phosphorylation of Akt, which was
present at low levels in the P-Alb liver at P15 (Figure 8C) but
was markedly increased at 10 weeks (Figure 8E, left panel).
Considering the postnatal expression of Cre recombinase driven
by the albumin promoter, the Pten gene was not fully disrupted
at P15, and Pten mRNA was present in the P-Alb, P/K-Alb,
and P/K-Alb/N livers by 50% of the control liver (Figure 8D).
Accordingly, the P-Alb, P/K-Alb, and P/K-Alb/N livers at P15
showed approximately 50% reduction of the Pten protein
compared with that in the control liver (Figure 8C), whereas it
was hardly detected in the 10-week-old Pten-Alb liver (Figure 8E,
right panel). Despite the partial depletion of Pten, Akt phosphor-
ylation, especially at T308, was markedly enhanced in the P/K-
Alb liver but not in the P-Alb liver (Figure 8C). Therefore, the
augmented Akt phosphorylation is independent of Pten reduc-
tion but is attributed to the disruption of the Keap1 gene. The
enhancement of Akt phosphorylation in the P/K-Alb liver was
absent in the P/K-Alb/N liver, which indicates that accumulated
Nrf2 is responsible for the increased phosphorylation of Akt. Nrf2
accumulation may have augmented the Akt phosphorylation in
the Keap1F/ forestomach and intestine (Figure 6F). Thus, the
activation of the PI3K-Akt pathway enhances Nrf2 activity by
increasing its nuclear availability, and the activated Nrf2 in turn
promotes the further activation of the PI3K-Akt pathway. This
positive feedback is one of the molecular mechanisms under-
lying the aggravating role of Nrf2 in cancer progression.
DISCUSSION
This study demonstrated a contribution of Nrf2 to cellular meta-
bolic activities in proliferating cells. While being a key regulator of
redox homeostasis in quiescent cells, Nrf2 activates the meta-
bolic genes in addition to the cytoprotective genes in prolifer-
ating cells, which is advantageous for proliferation and survival.
Metabolomic profilings revealed that Nrf2 promotes the purine
nucleotide synthesis and glutamine metabolism in the presence
of active PI3K-Akt signaling.
We identified six genes involved in the PPP and NADPH
production pathways as direct targets of Nrf2. Some of these
genes were listed asNrf2 targets in previousmicroarray analyses
conducted in mouse and human (Thimmulappa et al., 2002; Ma-
cLeod et al., 2009). These genes, except for Me1, were also
listed as direct target genes of Nrf2 in an earlier ChIP-seq anal-
ysis with anti-Nrf2 antibody using MEFs (Malhotra et al., 2010).
While a previous study focused on a cytoprotective aspect of
the PPP by analyzing the NADPH production as reducing equiv-
alents for the ROS elimination (Wu et al., 2011), this study
showed that the increase of the PPP activity accounts for the
Nrf2-dependent proliferation. We further identified the PI3K-
Akt pathway as one of the proliferative signals augmenting
Nrf2-dependent transcription. Since the PPP genes are strongly
activated by Nrf2 in proliferating cells in which PI3K-Akt pathway
is active, it is pertinent that the increased expression of the PPP
genes contributes to cell proliferation.
In addition to the PPP, or the pre-R5P steps of the nucleotide
synthesis, our metabolomic profilings revealed that Nrf2 strongly76 Cancer Cell 22, 66–79, July 10, 2012 ª2012 Elsevier Inc.enhances the latter part of the nucleotide synthesis, or the post-
R5P steps. Although we currently do not know the molecular
mechanisms how Nrf2 promotes the post-R5P steps, we spec-
ulate that the functional enhancement of Ppat and Mthfd2 is
one of the regulatory targets of Nrf2 (see Figures 1B, 4D, 6B,
and 8A). Nrf2 may also promote the glutamine-utilizing reactions
in the post-R5P steps, which could partly explain the glutamine
consumption mediated by Nrf2. We surmise that the post-
transcriptional regulation of key enzymes catalyzing the reac-
tions in the post-R5P steps explains the discordance between
the Nrf2-dependent transcriptome andmetabolome. In addition,
Nrf2 may indirectly promote the synthesis of 10-formyl-tetrahy-
drofolate (THF), which is an important substrate in post-R5P
steps, though supplying NADPH for the THF production. With
these possibilities, Nrf2 directly and/or indirectly controls the
complex multilayered regulation of the post-R5P steps.
The importance of glutathione has been recognized from
the viewpoint of the detoxification of xenobiotics and ROS.
However, recent studies have revealed that glutathione is critical
for cell proliferation (Reddy et al., 2007; 2008; Ishimoto et al.,
2011). Intriguingly, glutathione could not be replaced with
N-acetylcysteine for the proliferation-promoting activity, sug-
gesting that glutathione doesmore than simply correct the redox
balance to fully support cell proliferation (Reddy et al., 2008). The
metabolomic profiling showed that a substantial amount of
glutamine is directed into glutathione synthesis, to which Nrf2
makes a large contribution. Nrf2 induces GCL, a key enzyme
for glutathione synthesis, by directly activating the genes encod-
ing the catalytic and regulatory subunits, GCL catalytic subunit
(GCLC) and GCL modifier subunit (GCLM) (Moinova and Mul-
cahy, 1999; Solis et al., 2002; Bea et al., 2003; Sekhar et al.,
2003). Nrf2 also increases the supply of cysteine by directly
activating the gene encoding xCT (SLC7A11), a subunit of the
cystine transporter (Sasaki et al., 2002). Because Nrf2 strongly
activates Gclc, Gclm, and Slc7a11 in the presence of active
PI3K-Akt signaling (K.T., unpublished data), the enhancement
of glutathione synthesis is an important downstream of Nrf2 in
accelerating proliferation.
The functional interaction between the Keap1-Nrf2 pathway
and Pten-PI3K-Akt pathway has been reported in several studies
using cell lines. The pharmacological inhibition of the PI3K-Akt
pathway represses the nuclear translocation of Nrf2 (Harrison
et al., 2006; So et al., 2006). Consistent with these reports, we
have shown that activation of the PI3K-Akt pathway increases
the abundance of nuclear Nrf2. Recently GSK-3 was shown to
promote Keap1-independent degradation of Nrf2 (Rada et al.,
2011). Because Akt phosphorylates GSK-3 and inhibits its
activity (Cross et al., 1995), the active PI3K-Akt signaling should
stabilize Nrf2 through repressing GSK-3.
Unexpectedly, Akt phosphorylation was robustly augmented
in the P/K-Alb mice in Nrf2-dependent manner, which is consis-
tent with the previous report that Nrf2 positively regulates the
activation of Akt (Beyer et al., 2008). Considering that SREBP
has been suggested to induce the PPP genes when mTORC1
is activated (Du¨vel et al., 2010), Nrf2 could indirectly activate
the PPP through the Akt-mTORC1-SREBP axis in addition to
its role in the direct regulation of the PPP.
The genetic inactivation of PTEN leading to the constitutive
activation of PI3K-Akt signaling has been identified in many
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activate the PI3K-Akt signaling pathway (Yuan and Cantley,
2008). This study demonstrated the positive feedback loop bet-
ween the Pten-PI3K-Akt and Keap1-Nrf2 pathways, which
appears to be one of the most substantial mechanisms for pro-
moting the malignant evolution of cancers. Efficient cancelation
of the feedback would be an effective strategy for anti-cancer
therapy. It should be noted that a high level of Nrf2 accumulation,
which is achieved by the functional impairment of Keap1
combined with the sustained activation of PI3K-Akt pathway,
allows Nrf2 to get involved in the modulation of metabolism
under pathological conditions. In contrast, temporary accumula-
tion of Nrf2 at a low level is sufficient for Nrf2 to exert the cytopro-
tective function under physiological conditions. The marked
difference in Nrf2 activities between cancers and normal tissues
may provide a clue to the selective inhibition of Nrf2 in cancers.
EXPERIMENTAL PROCEDURES
Cell Culture
Two cell lines with KEAP1mutations (A549 and H2126) and two cell lines with
NRF2 mutations (LK2 and EBC1) were used. 293/CAT cells and 293/FALG-
Nrf2 cells were established previously (Zhang et al., 2007). MEFs were estab-
lished from Keap1/ and WT mouse embryos (Wakabayashi et al., 2003).
Microarray Analysis
Total RNA from A549 cells was labeled with Cy3. Samples were hybridized
to the Human Oligo Microarray (Agilent) according to the manufacturer’s
protocol. Arrays were scanned using the G2539A Microarray Scanner system
(Agilent), and the resulting data were analyzed using GeneSpring GX software
(Agilent).
Tumor Xenograft Experiment
A549 cells were subcutaneously injected into the upper back region of eight-
week-old male nude mice (BALB/C nu/nu). Tumor size was measured every
three days using calipers.
Animals
The generation of Nrf2+/, Keap1+/, Keap1F/+, and PtenF/+ mice has been
described (Itoh et al., 1997; Wakabayashi et al., 2003; Okawa et al., 2006;
Horie et al., 2004). PtenF/+ mice were a kind gift from Dr. Akira Suzuki (Kyushu
University). Alb-Cre transgenic mice were purchased from Jackson Labora-
tory. All mice were kept under specific pathogen-free conditions and treated
according to the regulations presented in The Standards for Human Care
and Use of Laboratory Animals of Tohoku University and Guidelines for Proper
Conduct of Animal Experiments by the Ministry of Education, Culture, Sports,
Science, and Technology of Japan. All the animal experiments were approved
at The Tohoku University Committee for Laboratory Animal Research.
Cell Viability Assay
MEFs were seeded at the initial density of 1 3 104 cells/well in 96-well plates
and cultured for 24 hr in the presence of 10% FBS or in the absence of FBS.
Cells were then treated with 1-chloro-2,4-dinitrobenzene (CDNB; WAKO
Pure Chemicals). After 12 hr of culturing, viable cell numbers were quantified
with the Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc.) according
to the manufacturer’s protocol.
BrdU Assay
BrdU was intraperitoneally injected into mice at the dose of 100 mg/kg body
weight. One hour after the injection, mice were sacrificed and analyzed using
BrdU Immunohistochemistry System (Merck Calbiochem).
Metabolite Measurements
Extracts were prepared from 2 to 6 3 106 cells or approximately 50 mg of
tissues with methanol containing Internal Standard Solution (Human Metabo-lime Technoligies) and analyzed using a capillary electrophoresis (CE)-
connected ESI-TOFMS system.
Statistical Analyses
All differences were analyzed with Student’s t test. A p value less than 0.05 was
considered to be statistically significant.
ACCESSION NUMBERS
The GEO database accession number for the microarray data is GSE28230.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, seven tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.ccr.2012.05.016.
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